Halozyme
Therapeutics, Inc. is a biopharmaceutical company developing and
commercializing products that advance patient care. The Company’s research
focuses on targeting the extracellular matrix an area outside the cell that
provides structural support in tissues and orchestrates many important
biological activities, including cell migration, signaling and survival. Its
research focuses primarily on human enzymes that alter the extracellular
matrix. Its recombinant human hyaluronidase or rHuPH20, temporarily degrades
hyaluronan (HA), a matrix component in the skin, and facilitates the dispersion
and absorption of drugs and fluids. It also focuses on developing novel enzymes
that may target other matrix structures for therapeutic benefit. Its Enhanze
technology is the platform for the delivery small and large molecules. Halozyme
Therapeu (NGM:HALO) is +1.54 - +24.02% from the previous close of $6.41. It
traded between $7.76 - 8.65 with total traded volume of 4892621 shares. At Current Market Price, HALO is in distance of +34.54% from its
50-day Moving Average price of $5.9091 and -6.33% from its 200-day Moving
Average price of $8.4872.
As
you can see by Friday's action, the FDA's ruling has considerably more bearing
on the unprofitable Halozyme than it does on ViroPharma, whose Cinryze is
already pumping out profits. As for me, I'm not nearly as excited about the
news -- at least not as excited as investors seem to be. In December, I noted
Halozyme's lofty valuation as a reason to avoid the stock, and I'm sticking
with that assertion even today. With losses expected well into 2014 and
possibly beyond, I see little reason to chase Halozyme higher.Craving more
input? Start by adding Halozyme Therapeutics to your free and personalized
watchlist so you can keep up on the latest news with the company.
